Feb 11 (Reuters) - Australia's CSL Ltd CSL.AX reported a 5% rise in its first-half profit on Tuesday, boosted by growth in its core immunoglobulin business across geographies.
The biotech giant said that its underlying net profit after tax attributable for the six months ended December 31 was $2.11 billion, on a constant currency basis, compared with $2.06 billion reported a year ago.
(Reporting by Aaditya Govind Rao and Shivangi Lahiri in Bengaluru; Editing by Alan Barona)
((Shivangi.Lahiri@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.